SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown cardioprotective effects in patients with diabetes, suggesting potential benefits in reducing AF incidence.<h4>Methods</h4>We retrospectively analyzed clinical data from patients with T2DM diagnosed with DCM treated at the First Affiliated Hospital of Xi'an Jiaotong University between January 2018 and January 2024.